Klee Justin B. 4

4 · Amylyx Pharmaceuticals, Inc. · Filed Mar 9, 2026

AI-generated summary of this filing

Updated Mar 9, 2026

Amylyx (AMLX) CEO Justin Klee Receives RSU & Option Awards

What Happened

Justin B. Klee, CEO of Amylyx Pharmaceuticals (AMLX), was granted equity awards on 2026-03-05: 248,865 restricted stock units (RSUs) and a 373,295-share derivative award. Both grants were reported as acquisitions at $0.00 (no cash paid). These are compensation awards, not open-market purchases or sales.

Key Details

Transaction date: March 5, 2026. Form 4 filed March 9, 2026 (within the 2 business-day filing window — timely).
Reported amounts/prices: 248,865 shares @ $0.00 (RSU award); 373,295 shares @ $0.00 (derivative award).
Shares owned after transaction: Not specified in the filing.
Footnotes:
- F1 (RSUs): The 248,865 RSUs vest in four equal annual installments, first vesting March 1, 2027, subject to continued service.
- F2 (derivative): 25% of the derivative award vests and becomes exercisable on March 1, 2027; remaining shares vest monthly over the next 36 months, subject to continued service — indicating an option-like vesting schedule.
No indication of tax withholding sale, 10b5-1 plan, or other special sale conditions in the filing.

Context

These grants are standard executive compensation intended to retain and incentivize the CEO; they do not represent an immediate cash investment by the insider. Because the awards vest over time and are service-contingent, they do not signal an immediate market buy or sell by the CEO. For retail investors, such grants are routine but worth noting for future potential insider stock sales or exercise activity as vesting dates approach.

Form 4

Period: 2026-03-05

DirectorCo-Chief Executive Officer

Transactions

Award
Common Stock
[F1]
2026-03-05+248,865→ 3,583,481 total
Award
Stock Option (Right to Buy)
[F2]
2026-03-05+373,295→ 373,295 total
Exercise: $14.10Exp: 2036-03-05→ Common Stock (373,295 underlying)

Footnotes (2)

[F1]The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
[F2]25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Signature

/s/ Joshua B. Cohen, as Attorney in Fact|2026-03-09

1 file